Search Results - "Wilkinson, Robert W."

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment by Hewitt, Susannah L, Bailey, Dyane, Zielinski, John, Apte, Ameya, Musenge, Faith, Karp, Russell, Burke, Shannon, Garcon, Fabien, Mishra, Ankita, Gurumurthy, Sushma, Watkins, Amanda, Arnold, Kristen, Moynihan, James, Clancy-Thompson, Eleanor, Mulgrew, Kathy, Adjei, Grace, Deschler, Katharina, Potz, Darren, Moody, Gordon, Leinster, David A, Novick, Steve, Sulikowski, Michal, Bagnall, Chris, Martin, Philip, Lapointe, Jean-Martin, Si, Han, Morehouse, Chris, Sedic, Maja, Wilkinson, Robert W, Herbst, Ronald, Frederick, Joshua P, Luheshi, Nadia

“…While immune checkpoint inhibitors such as anti-PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated…”
Get full text

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype by Candido, Juliana B., Morton, Jennifer P., Bailey, Peter, Campbell, Andrew D., Karim, Saadia A., Jamieson, Thomas, Lapienyte, Laura, Gopinathan, Aarthi, Clark, William, McGhee, Ewan J., Wang, Jun, Escorcio-Correia, Monica, Zollinger, Raphael, Roshani, Rozita, Drew, Lisa, Rishi, Loveena, Arkell, Rebecca, Evans, T.R. Jeffry, Nixon, Colin, Jodrell, Duncan I., Wilkinson, Robert W., Biankin, Andrew V., Barry, Simon T., Balkwill, Frances R., Sansom, Owen J.

“…Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most…”
Get full text

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody by Stewart, Ross, Morrow, Michelle, Hammond, Scott A, Mulgrew, Kathy, Marcus, Danielle, Poon, Edmund, Watkins, Amanda, Mullins, Stefanie, Chodorge, Matthieu, Andrews, John, Bannister, David, Dick, Emily, Crawford, Nicola, Parmentier, Julie, Alimzhanov, Marat, Babcook, John S, Foltz, Ian N, Buchanan, Andrew, Bedian, Vahe, Wilkinson, Robert W, McCourt, Matthew

“…Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation. Many tumors can upregulate expression of…”
Get more information

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery by Mosely, Suzanne I S, Prime, John E, Sainson, Richard C A, Koopmann, Jens-Oliver, Wang, Dennis Y Q, Greenawalt, Danielle M, Ahdesmaki, Miika J, Leyland, Rebecca, Mullins, Stefanie, Pacelli, Luciano, Marcus, Danielle, Anderton, Judith, Watkins, Amanda, Coates Ulrichsen, Jane, Brohawn, Philip, Higgs, Brandon W, McCourt, Matthew, Jones, Hazel, Harper, James A, Morrow, Michelle, Valge-Archer, Viia, Stewart, Ross, Dovedi, Simon J, Wilkinson, Robert W

“…Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these models are still not…”
Get more information

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies by Mullins, Stefanie R., Vasilakos, John P., Deschler, Katharina, Grigsby, Iwen, Gillis, Pete, John, Julius, Elder, Matthew J., Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon J., Leishman, Andrew J., Luheshi, Nadia, Elvecrog, James, Tilahun, Ashenafi, Goodwin, Richard, Herbst, Ronald, Tomai, Mark A., Wilkinson, Robert W.

“…BackgroundImmune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically…”
Get full text

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer by Berlato, Chiara, Khan, Moddasar N, Schioppa, Tiziana, Thompson, Richard, Maniati, Eleni, Montfort, Anne, Jangani, Maryam, Canosa, Monica, Kulbe, Hagen, Hagemann, Urs B, Duncan, Alexander R, Fletcher, Laura, Wilkinson, Robert W, Powles, Thomas, Quezada, Sergio A, Balkwill, Frances R

“…Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was…”
Get full text

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade by Wilkinson, Robert W, Leishman, Andrew J

“…Significant advances have been made to identify effective therapies that either restore or generate a patient's immune response to cancer, so-called…”
Get full text

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer by Stewart, Ross, Hammond, Scott A, Oberst, Michael, Wilkinson, Robert W

“…Antibodies targeting T-cell inhibitory pathways, such as CTLA-4 and PD-1/PD-L1, are emerging as an important class of cancer therapeutics, and a next…”
Get full text

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation by Lopez-Pelaez, Marta, Young, Lucy, Vazquez-Chantada, Mercedes, Nelson, Nadine, Durant, Steve, Wilkinson, Robert W., Poon, Edmund, Gaspar, Miguel, Valge-Archer, Viia, Smith, Paul, Dovedi, Simon J.

“…The concept of exploiting tumor intrinsic deficiencies in DNA damage repair mechanisms by inhibiting compensatory DNA repair pathways is well established. For…”
Get full text

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments by Sitnikova, Suzanne I., Walker, Jennifer A., Prickett, Laura B., Morrow, Michelle, Valge-Archer, Viia E., Robinson, Matthew J., Wilkinson, Robert W., Dovedi, Simon J.

“…Introduction Immuno-oncology (IO) research relies heavily on murine syngeneic tumor models. However, whilst the average age for a cancer diagnosis is 60 years…”
Get full text

AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis by WILKINSON, Robert W, ODEDRA, Rajesh, BYTH, Kate F, BARRASS, Nigel C, MUNDT, Kirsten E, FOOTE, Kevin M, HERON, Nicola M, JUNG, Frederic H, MORTLOCK, Andrew A, BOYLE, F. Thomas, GREEN, Stephen, HEATON, Simon P, WEDGE, Stephen R, KEEN, Nicholas J, CRAFTER, Claire, FOSTER, John R, BRADY, Madeleine C, BIGLEY, Alison, BROWN, Elaine

“…Purpose: In the current study, we examined the in vivo effects of AZD1152, a novel and specific inhibitor of Aurora kinase activity (with selectivity for…”
Get full text

Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) by HOLT, Sarah V, LOGIE, Armelle, WILKINSON, Robert W, GUICHARD, Sylvie M, SMITH, Paul D, DAVIES, Barry R, ALFEREZ, Denis, RUNSWICK, Sarah, FENTON, Sarah, CHRESTA, Christine M, YI GU, JINGCHUAN ZHANG, WU, Yi-Long

“…The mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/AKT signaling pathways interact at multiple nodes in cancer, including at mTOR…”
Get full text

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer by HICKINSON, D. Mark, KLINOWSKA, Teresa, MILLS, Elizabeth, GROSIOS, Konstantina, SMITH, Paul, BARLAAM, Bernard, WILKINSON, Robert W, OGILVIE, Donald, SPEAKE, Georgina, VINCENT, John, TRIGWELL, Cath, ANDERTON, Judith, BECK, Sarah, MARSHALL, Gayle, DAVENPORT, Sara, CALLIS, Rowena

“…Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth…”
Get full text

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity by Nelson, Nadine, Lopez-Pelaez, Marta, Palazon, Asis, Poon, Edmund, De La Roche, Maike, Barry, Simon, Valge-Archer, Viia, Wilkinson, Robert W., Dovedi, Simon J., Smith, Paul D.

“…In vitro assays that evaluate CD8 + T cell-mediated cytotoxicity are important to aid in the development of novel therapeutic approaches to enhance anti-tumor…”
Get full text

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer by Schofield, Darren J, Percival-Alwyn, Jennifer, Rytelewski, Mateusz, Hood, John, Rothstein, Raymond, Wetzel, Leslie, McGlinchey, Kelly, Adjei, Grace, Watkins, Amanda, Machiesky, LeeAnn, Chen, Weimin, Andrews, John, Groves, Maria, Morrow, Michelle, Stewart, Ross A, Leinster, Andrew, Wilkinson, Robert W, Hammond, Scott A, Luheshi, Nadia, Dobson, Claire, Oberst, Michael

“…Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of…”
Get full text

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment by Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S, Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E, Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J, Smith, Paul D, Stewart, Ross, Wilkinson, Robert W

“…T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK…”
Get full text

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 by Green, Tim P., Fennell, Mike, Whittaker, Robin, Curwen, Jon, Jacobs, Vivien, Allen, Jack, Logie, Armelle, Hargreaves, Judith, Hickinson, D. Mark, Wilkinson, Robert W., Elvin, Paul, Boyer, Brigitte, Carragher, Neil, Plé, Patrick A., Bermingham, Alun, Holdgate, Geoffrey A., Ward, Walter H.J., Hennequin, Laurent F., Davies, Barry R., Costello, Gerard F.

“…AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive effects in vitro, and inhibited metastasis in a murine model of…”
Get full text

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts by Byth, Kate F, Thomas, Andrew, Hughes, Gareth, Forder, Cheryl, McGregor, Alexandra, Geh, Catherine, Oakes, Sandra, Green, Clive, Walker, Mike, Newcombe, Nicholas, Green, Stephen, Growcott, Jim, Barker, Andy, Wilkinson, Robert W

“…Deregulation of the cell cycle has long been recognized as an essential driver of tumorigenesis, and agents that selectively target key cell cycle components…”
Get full text

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo by OKE, Adedayo, PEARCE, Daniel, WILKINSON, Robert W, CRAFTER, Claire, ODEDRA, Rajesh, CAVENAGH, Jamie, FITZGIBBON, Jude, LISTEN, Andrew T, JOEL, Simon, BONNET, Dominique

“…Aurora kinases play a critical role in regulating mitosis and cell division, and their overexpression has been implicated in the survival and proliferation of…”
Get full text

Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression by Hair, James, Robinson, Matthew J, Wilkinson, Robert W, Dovedi, Simon J

“…The field of Immuno-Oncology (IO) is evolving to utilise novel antibody backbones that can co-target multiple cell-surface stimulatory and inhibitory…”
Get full text